Moreover, our results shed light on one facet of the resistance process of ETP-ALL to LSD1i that could explain the inefficiency of LSD1i as monotherapy [11], and highlights the need for targeted therapy against BCL2 expression in ETP-ALL context to potentialize the therapeutic activity of LSD1i in ETP-ALL. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.